Recent Data in Genitourinary Cancers at ASCO 2023

home / data-dialogue-with-the-oncology-brothers / recent-data-in-genitourinary-cancers-at-asco-2023

The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Toni Choueiri, MD, following the 2023 ASCO Annual Meeting to discuss recent data updates in the genitourinary cancer space.

Experts on genitourinary cancers

EP. 1: TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Toni K. Choueiri, MD
July 13th 2023

Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.

Experts on genitourinary cancers

EP. 2: CLEAR and CONTACT-03: Data Updates in Metastatic Renal Cell Carcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Toni K. Choueiri, MD
July 13th 2023

Following ASCO 2023, experts in oncology review recent data from the CLEAR and CONTACT-03 clinical trials in the metastatic renal cell carcinoma space.

Experts on genitourinary cancers

EP. 3: THOR: Erdafitinib vs Chemotherapy in Metastatic Urothelial Cancer with FGFR Alterations

Rohit Gosain, MD;Rahul Gosain, MD;Toni K. Choueiri, MD
July 13th 2023

Expert oncologists offer insights on recent data from the THOR trial, which compared erdafitinib with chemotherapy in patients with metastatic bladder cancer.

Experts on genitourinary cancers

EP. 4: Closing Thoughts on Data Updates from ASCO 2023 for GU Cancers

Rohit Gosain, MD;Rahul Gosain, MD;Toni K. Choueiri, MD
July 13th 2023

Rohit Gosain, MD, and Rahul Gosain, MD, summarize recent key data updates for genitourinary cancers following the 2023 ASCO Annual Meeting.